Fucosylated chondroitin sulfate inhibits plasma thrombin generation via targeting of the factor IXa heparin-binding exosite

Blood

Volumn 114, Issue 14, 2009, Pages 3092-3100

  Buyue, Yang ^a   Sheehan, John P ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8A; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9A; CHONDROITIN SULFATE; DEPOLYMERIZED HOLOTHURIAN GLYCOAMINOGLYCAN; ENZYME PRECURSOR; HEPARIN; SERINE PROTEINASE INHIBITOR; THROMBIN; THROMBOPLASTIN; UNCLASSIFIED DRUG;

ARTICLE; BLOOD CLOTTING FACTOR DEFICIENCY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BINDING SITE; DRUG MECHANISM; DRUG TARGETING; EMBRYO; ENZYME ACTIVATION; FUCOSYLATION; HUMAN; HUMAN CELL; INHIBITION KINETICS; PRIORITY JOURNAL;

BINDING SITES; BLOTTING, WESTERN; CHONDROITIN SULFATES; CYSTEINE ENDOPEPTIDASES; FACTOR IXA; FACTOR VIIIA; HUMANS; MUTATION; NEOPLASM PROTEINS; SERPINS; THROMBIN; THROMBOPLASTIN;

EID: 70449464372     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-02-203661     Document Type: Article

References (42)

1. Yoshida K, Minami Y. Structure of DHG, a depolymerized glycosaminoglycan from sea cucumber, Stichopus japonicus. Tetrahedron Lett. 1992;33:4959.
2. Tsukamoto T, Ushio T, Haginaka J. Chiral resolution of basic drugs by capillary electrophoresis with new glycosaminoglycans. J Chromatogr A. 1999;864:163-171.
3. Nagase H, Kitazato KT, Sasaki E, Hattori M, Kitazato K, Saito H. Antithrombin III-independent effect of depolymerized holothurian glycosaminoglycan (DHG) on acute thromboembolism in mice. Thromb Haemost. 1997;77:399-402. (Pubitemid 27084937)
4. Kitazato K, Kitazato KT, Nagase H, Minamiguchi K. DHG, a new depolymerized holothurian glycosaminoglycan, exerts an antithrombotic effect with less bleeding than unfractionated or low molecular weight heparin, in rats. Thromb Res. 1996;84:111-120. (Pubitemid 26355266)
5. Minamiguchi K, Kitazato KT, Sasaki E, Nagase H, Kitazato K. The anticoagulant and hemorrhagic effects of DHG, a new depolymerized holothurian glycosaminoglycan, on experimental hemodialysis in dogs. Thromb Haemost. 1997;77:1148-1153. (Pubitemid 27311985)
6. Minamiguchi K, Kitazato KT, Nagase H, Sasaki E, Ohwada K, Kitazato K. Depolymerized holothurian glycosaminoglycan (DHG), a novel alternative anticoagulant for hemodialysis, is safe and effective in a dog renal failure model. Kidney Int. 2003;63:1548-1555. (Pubitemid 36350021)
7. Minamiguchi K, Nagase H, Kitazato KT, Kitazato K. Interaction of a new depolymerized holothurian glycosaminoglycan with proteins in human plasma. Thromb Res. 1996;83:253-264. (Pubitemid 26274427)
8. Kitazato K, Kitazato KT, Sasaki E, Minamiguchi K, Nagase H. Prolonged bleeding time induced by anticoagulant glycosaminoglycans in dogs is associated with the inhibition of thrombin-induced platelet aggregation. Thromb Res. 2003;112:83-91. (Pubitemid 38167590)
9. Nagase H, Enjyoji K, Minamiguchi K, et al. Depolymerized holothurian glycosaminoglycan with novel anticoagulant actions: antithrombin III- and heparin cofactor II-independent inhibition of factor X activation by factor IXa-factor VIIIa complex and heparin cofactor II-dependent inhibition of thrombin. Blood. 1995;85:1527-1534.
10. Nagase H, Enjyoji K, Shima M, et al. Effect of depolymerized holothurian glycosaminoglycan (DHG) on the activation of factor VIII and factor V by thrombin. J Biochem (Tokyo). 1996;119:63-69. (Pubitemid 26048770)
11. Sheehan JP, Walke EN. Depolymerized holothurian glycosaminoglycan and heparin inhibit the intrinsic tenase complex by a common antithrombin- independent mechanism. Blood. 2006;107:3876-3882.
12. Hoffman M, Monroe DM, Oliver JA, Roberts HR. Factors IXa and Xa play distinct roles in tissue factor-dependent initiation of coagulation. Blood. 1995;86:1794-1801.
13. Lawson JH, Kalafatis M, Stram S, Mann KG. A model for the tissue factor pathway to thrombin. I. An empirical study. J Biol Chem. 1994;269:23357-23366. (Pubitemid 24283329)
14. Rand MD, Lock JB, van t Veer C, Gaffney DP, Mann KG. Blood clotting in minimally altered whole blood. Blood. 1996;88:3432-3445.
15. Hockin MF, Jones KC, Everse SJ, Mann KG. A model for the stoichiometric regulation of blood coagulation. J Biol Chem. 2002;277:18322-18333. (Pubitemid 34952376)
16. Bajaj SP, Schmidt AE, Mathur A, et al. Factor IXa: factor VIIIa interaction: helix 330-338 of factor ixa interacts with residues 558-565 and spatially adjacent regions of the a2 subunit of factor VIIIa. J Biol Chem. 2001;276:16302-16309. (Pubitemid 37391674)
17. Yuan QP, Walke EN, Sheehan JP. The factor IXa heparin-binding exosite is a cofactor interactive site: mechanism for antithrombin-independent inhibition of intrinsic tenase by heparin. Biochemistry. 2005;44:3615-3625.
18. Misenheimer TM, Buyue Y, Sheehan JP. The heparin-binding exosite is critical to allosteric activation of factor IXa in the intrinsic tenase complex: the role of arginine 165 and factor X. Biochemistry. 2007;46:7886-7895. (Pubitemid 47016070)
19. Buyue Y, Whinna HC, Sheehan JP. The heparin-binding exosite of factor IXa is a critical regulator of plasma thrombin generation and venous thrombosis. Blood. 2008;112:3234-3241.
20. MacDonald RC, MacDonald RI, Menco BP, Takeshita K, Subbarao NK, Hu LR. Small-volume extrusion apparatus for preparation of large, unilamellar vesicles. Biochim Biophys Acta. 1991;1061:297-303.
21. Chang J, Jin J, Lollar P, et al. Changing residue 338 in human factor IX from arginine to alanine causes an increase in catalytic activity. J Biol Chem. 1998;273:12089-12094. (Pubitemid 28240568)
22. Hemker HC, Giesen P, Al Dieri R, et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb. 2003;33:4-15. (Pubitemid 37449290)
23. Limbird L. Cell Surface Receptors: A Short Course on Theory and Methods. 2nd Ed. Boston, MA: Kluwer Academic Publishers; 1995.
24. Luddington R, Baglin T. Clinical measurement of thrombin generation by calibrated automated thrombography requires contact factor inhibition. J Thromb Haemost. 2004;2:1954-1959. (Pubitemid 40192749)
25. Gerotziafas GT, Depasse F, Busson J, Leflem L, Elalamy I, Samama MM. Towards a standardization of thrombin generation assessment: the influence of tissue factor, platelets and phospholipids concentration on the normal values of Thrombogram-Thrombinoscope assay. Thromb J. 2005;3:16. (Pubitemid 41601358)
26. Brummel-Ziedins KE, Pouliot RL, Mann KG. Thrombin generation: phenotypic quantitation. J Thromb Haemost. 2004;2:281-288.
27. Brummel-Ziedins K, Vossen CY, Rosendaal FR, Umezaki K, Mann KG. The plasma hemostatic proteome: thrombin generation in healthy individuals. J Thromb Haemost. 2005;3:1472-1481. (Pubitemid 41725206)
28. Brummel-Ziedins KE, Vossen CY, Butenas S, Mann KG, Rosendaal FR. Thrombin generation profiles in deep venous thrombosis. J Thromb Haemost. 2005;3:2497-2505. (Pubitemid 41727167)
29. Hron G, Kollars M, Binder BR, Eichinger S, Kyrle PA. Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation. JAMA. 2006;296:397-402. (Pubitemid 44127523)
30. Tripodi A, Legnani C, Chantarangkul V, Cosmi B, Palareti G, Mannucci PM. High thrombin generation measured in the presence of thrombomodulin is associated with an increased risk of recurrent venous thromboembolism. J Thromb Haemost. 2008;6:1327-1333. (Pubitemid 352016312)
31. Besser M, Baglin C, Luddington R, van Hylckama Vlieg A, Baglin T. High rate of unprovoked recurrent venous thrombosis is associated with high thrombin-generating potential in a prospective cohort study. J Thromb Haemost. 2008;6:1720-1725.
32. Marlar RA, Kleiss AJ, Griffin JH. An alternative extrinsic pathway of human blood coagulation. Blood. 1982;60:1353-1358. (Pubitemid 13211374)
33. Pike RN, Buckle AM, le Bonniec BF, Church FC. Control of the coagulation system by serpins. Getting by with a little help from glycosaminoglycans. FEBS J. 2005;272:4842-4851.
34. Barrow RT, Parker ET, Krishnaswamy S, Lollar P. Inhibition by heparin of the human blood coagulation intrinsic pathway factor X activator. J Biol Chem. 1994;269:26796-26800. (Pubitemid 24332874)
35. Sheehan JP, Kobbervig CE, Kirkpatrick HM. Heparin inhibits the intrinsic tenase complex by interacting with an exosite on factor IXa. Biochemistry. 2003;42:11316-11325.
36. Bousser MG, Bouthier J, Buller HR, et al. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial. Lancet. 2008;371:315-321.
37. Buller HR, Cohen AT, Davidson B, et al. Extended prophylaxis of venous thromboembolism with idraparinux. N Engl J Med. 2007;357:1105-1112. (Pubitemid 47443215)
38. Benedict CR, Ryan J, Wolitzky B, et al. Active site-blocked factor IXa prevents intravascular thrombus formation in the coronary vasculature without inhibiting extravascular coagulation in a canine thrombosis model. J Clin Invest. 1991;88:1760-1765.
39. Choudhri TF, Hoh BL, Prestigiacomo CJ, et al. Targeted inhibition of intrinsic coagulation limits cerebral injury in stroke without increasing intracerebral hemorrhage. J Exp Med. 1999;190:91-99.
40. Spanier TB, Chen JM, Oz MC, et al. Selective anticoagulation with active site-blocked factor IXA suggests separate roles for intrinsic and extrinsic coagulation pathways in cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1998;116:860-869.
41. Feuerstein GZ, Patel A, Toomey JR, et al. Antithrombotic efficacy of a novel murine antihuman factor IX antibody in rats. Arterioscler Thromb Vasc Biol. 1999;19:2554-2562. (Pubitemid 29477859)
42. Refino CJ, Jeet S, DeGuzman L, Bunting S, Kirchhofer D. A human antibody that inhibits factor IX/IXa function potently inhibits arterial thrombosis without increasing bleeding. Arterioscler Thromb Vasc Biol. 2002;22:517-522. (Pubitemid 34223419)